Pfizer and Arvinas Report Positive Trial Results for Breast Cancer Drug

Published 1 days agoPFE

Pfizer and Arvinas Report Positive Trial Results for Breast Cancer Drug

Pfizer and Arvinas have announced promising outcomes from their Phase 3 VERITAC-2 trial for vepdegestrant, an experimental breast cancer drug. The trial showed that vepdegestrant effectively delayed disease progression in patients with ESR1 gene mutations, surpassing AstraZeneca's Faslodex. Reuters highlighted that the median progression-free survival for these patients was five months with vepdegestrant, compared to just two months with Faslodex.

Additionally, in the broader patient population, vepdegestrant offered a slight improvement in median progression-free survival at 3.8 months, compared to 3.6 months with Faslodex. One key advantage of vepdegestrant noted in the trial is its oral administration, which offers greater convenience than Faslodex's intramuscular injection. Analysts forecast a potential peak in sales reaching $576 million by 2032.

Following these successful results, Pfizer and Arvinas are preparing to submit their findings to regulatory authorities worldwide, seeking approval for vepdegestrant. The oral convenience and efficacy of the drug mark a significant advance in treatment options for breast cancer patients, especially those with certain genetic mutations.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Amazon Faces Increased Oversight by German Regulator

Amazon Faces Increased Oversight by German Regulator

15 minutes agoAMZN

Amazon has not been found to have breached competition law in Germany, according to recent reports. The German Federal Court of Justice, in April 2024, underscored Amazon's influence by confirming the Bundeskartellamt's classification of the company as having 'paramount significance for competition across markets.' This ruling subjects Amazon to heightened scrutiny under Germany's competition laws. Back in November 2022, the Bundeskartellamt extended its investigation into Amazon under Section 19a of the German Competition Act. This was part of a broader effort to ensure that Amazon's business practices, particularly its pricing mechanisms, align with new regulations intended for larger digital platforms. Despite these ongoing investigations, Reuters has noted that there remain no specific findings regarding Amazon's pricing mechanisms breaching competition laws. These developments reflect the ongoing watchful stance of regulators towards Amazon as it navigates a regulatory landscape that is becoming increasingly stringent, especially for major digital corporations. The focus remains on ensuring compliance with amended competition laws without any recent findings against Amazon's practices in Germany.

Boeing Stock Ratings Mixed Amid Trade Tensions and Contract Wins

Boeing Stock Ratings Mixed Amid Trade Tensions and Contract Wins

30 minutes agoBA

Recent updates reveal mixed perspectives on Boeing's stock ratings amid significant developments. As of April 28, 2025, Bank of America maintained a 'Neutral' rating for Boeing, with a target price of $185, contradicting assertions that their rating shifted to 'Buy' due to trade deals involving the company's planes. Contrastingly, other financial institutions have shown increased optimism. Melius Research upgraded Boeing's rating to 'Buy' from 'Hold' on March 24, 2025, following the company's contract victory over Lockheed Martin for the Next Generation Air Dominance program. Similarly, in February 2025, Citigroup reaffirmed its 'Buy' rating for Boeing, setting a price target of $210 per share. Despite positive developments like the $10 billion order from the UK in May 2025, Boeing faces challenges including halted imports by China in April 2025, as reported by Axios, amid U.S. tariff tensions. This illustrates the complex trade landscape Boeing must navigate while balancing opportunities and potential risks.

Applied Digital Expands AI Capacity with CoreWeave Partnership

Applied Digital Expands AI Capacity with CoreWeave Partnership

45 minutes agoAPLD

Applied Digital Corporation has announced a major new lease agreement with CoreWeave, a prominent GPU cloud provider, to boost its AI data center operations. This move is part of Applied Digital's efforts to enhance its infrastructure to support high-performance computing (HPC) and AI workloads. The partnership aims to address the increasing demand for AI services, aligning with the company's strategic direction to expand its capacity in this booming sector. Following the announcement of the collaboration with CoreWeave, there was a significant positive response in the market, evidenced by a notable surge in Applied Digital's stock price. This investor enthusiasm likely reflects confidence in the company's potential to grow its AI infrastructure. Furthermore, Applied Digital reported a 67% increase in revenue year-over-year for the first quarter of 2025, which was supported by the expansion of its data center hosting operations and initial cloud-services business initiatives, as reported by tastylive.com. The strategic partnership with CoreWeave ties into a broader industry pattern where companies are making large investments in AI infrastructure to support the rising demand for AI and HPC services. This agreement illustrates Applied Digital's commitment to enhancing its AI capabilities, indicating a robust approach to navigating the fast-growing AI market. According to ft.com, the partnership fits well with ongoing industry trends, emphasizing the company's proactive stance in meeting these technological advancements.

Vera Therapeutics' Stock Soars on Positive IgAN Trial Results

Vera Therapeutics' Stock Soars on Positive IgAN Trial Results

1 hours agoVERA

Vera Therapeutics has experienced a significant surge in its stock value following the successful outcome of its Phase 3 trial for the drug atacicept in treating IgA Nephropathy (IgAN). The company's ORIGIN 3 trial showed atacicept's ability to considerably reduce proteinuria and maintain stable kidney function in patients, marking a promising step forward in addressing this serious kidney disease. In addition to the optimistic trial results, atacicept has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for its role in treating IgAN, as reported by Reuters. This designation is critical as it helps fast-track the drug's development and review process. Vera Therapeutics intends to submit a Biologics License Application (BLA) for atacicept in the latter half of 2025, with hopes of commercial availability by 2026. On the financial front, Vera Therapeutics is in a strong position, boasting approximately $353.2 million in cash and marketable assets as of September 30, 2024. This financial backing is expected to support the company's ongoing and future clinical development initiatives, reinforcing its status as a key player in the IgAN treatment landscape.